

10/523172

JT12 Rec'd PCT/PTO 28 JAN 2005

Doc No. 4126-4023

#3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): del Pozo Losada et al.

Group Art Unit: tba

Serial No.: tba

Examiner: tba

Filed: January 28, 2005

For: TOTAL SYNTHESIS OF MYRIAPORONES

INFORMATION DISCLOSURE STATEMENT

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is filed in accordance with 37 C.F.R.

§§1.56, 1.97 and 1.98. The items listed on Form PTO-1449, a copy of which is enclosed, are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

1. ☐ For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed:
2. ☐ For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, a concise explanation of the relevance of that item is incorporated in the specification of the above-identified application.
3. ☐ Any copy of the items listed on the enclosed copy of Form PTO-1449 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in application Serial No. _____, filed _____.

4. ☒ No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with:

- ☐ 37 C.F.R. §1.97(b)(1), within three months of the filing date of a national application other than a CPA; or
- ☒ 37 C.F.R. §1.97(b)(2), within three months of the date of entry into the national stage as set forth in §1.491 in an international application; or
- ☐ 37 C.F.R. §1.97(b)(3), before the mailing date of a first Office action on the merits; or
- ☐ 37 C.F.R. §1.97(b)(4), before the mailing date of a first office action after the filing of an RCE under §1.114.

☒ The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 13-4500., Order No. 4126-4023. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,
MORGAN & FINNEGAN, L.L.P.

Dated: January 28, 2005

By: _____

Michael A. Willis
Kenneth H. Sonnenfeld / Michael A. Willis
Reg. No. 33,285 / Reg. No. 53,913

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.
3 World Financial Center
New York, NY 10281-2101
(212) 415-8700 Telephone
(212) 415-8701 Facsimile

4. ☒ No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with:

- ☐ 37 C.F.R. §1.97(b)(1), within three months of the filing date of a national application other than a CPA; or
- ☒ 37 C.F.R. §1.97(b)(2), within three months of the date of entry into the national stage as set forth in §1.491 in an international application; or
- ☐ 37 C.F.R. §1.97(b)(3), before the mailing date of a first Office action on the merits; or
- ☐ 37 C.F.R. §1.97(b)(4), before the mailing date of a first office action after the filing of an RCE under §1.114.

☒ The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 13-4500., Order No. 4126-4023. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,
MORGAN & FINNEGAN, L.L.P.

Dated: January 28, 2005

By: Michael A. Willis

Kenneth H. Sonnenfeld / Michael A. Willis
Reg. No. 33,285 / Reg. No. 53,913

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.
3 World Financial Center
New York, NY 10281-2101
(212) 415-8700 Telephone
(212) 415-8701 Facsimile

FORM PTO-1449 INFORMATION DISCLOSURE CITATION				Attorney Docket: 4126-4023		Serial tba / 523172	
				Applicant: de Pozo Losada et al.			
				Filing Date: January 28, 2005		Group Art Unit: tba	
U.S. PATENT DOCUMENTS							
Examiner Initial		Patent Number	Issue Date	Name	Class	Sub-Class	Filing Date
	US	5,514,708	May 1996	Rinehart et al	514	460	
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Patent Number	Publication Date	Country	Class	Sub- Class	Translati on
							<input type="checkbox"/> Yes <input type="checkbox"/> No
							<input type="checkbox"/> Yes <input type="checkbox"/> No
							<input type="checkbox"/> Yes <input type="checkbox"/> No
OTHER DOCUMENTS (Including Author, Title, Date, etc.)							
	Taylor et al, "A Divergent Approach to the Myriaporones and Tedanolide: Enantioselective Preparation of the Common Intermediate" Tetrahedron Letters, vol. 39, no. 51, pages 9361-9364, Dec. 17, 1998.						
	Roush et al, "Studies on the Synthesis of Tedanolide: Synthesis of the C(5)-C(21) Segment via a Highly Stereoselective Fragment Assembly Aldol Reaction of a Chiral β,γ -Unsaturated Methyl Ketone" Organic Letters, vol. 1, no. 1, pages 95-98, 1999.						
	Taylor et al, "Zirconium-mediated allylations: A diastereoselective approach to the myriaporones" Abstracts of Papers, 218 th National Meeting of the American Chemical Society, vol. 218, no. 1-2, page ORGN 591, August 1999.						
	Taylor et al, "Synthetic Efforts toward the total synthesis of myriaporone 1" Abstracts of Papers, 218 th National Meeting of the American Chemical Society, vol. 218, no. 1-2, page ORGN 621, August 1999.						
	Zheng et al, "Studies on the synthesis of myriaporones: stereoselective synthesis of the C5-C13 fragment starting from D-glucose via regioselective reductive opening of methoxybenzylidene acetal" Chemical & Pharmaceutical Bulletin, vol. 48, no. 11, pages 1761-1765, November 2000.						
Examiner				Date Considered			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							